港A疫苗股集體大跌 復星醫藥(600196.SH)跌停
格隆匯8月6日丨港A兩地此前表現強勢的疫苗股今日集體大跌。A股復星醫藥跌停,康希諾、沃森生物和康泰生物跌超7%,西藏藥業跌超6%。港股復星醫藥跌超10%,康希諾跌超2%。騰盛博藥-B(2137)5日公吿,其新冠中和抗體已完成美國三期臨牀試驗的846病人的入組,臨牀前毒理實驗顯示對Delta病毒有效。若後續數據積極,將會有被用於EUA的可能性,這也將是中國唯一一個獲批的中和抗體。另外,國藥集團中國生物官微8月4日發文稱,國藥集團中國生物楊曉明研究員團隊最新發現針對德爾塔變異株有效的單克隆抗體,中和活性IC50高達5ng/ml。這意味着,單抗對德爾塔(Delta)等新冠變異株有效,新冠肺炎治療有望迎來特效藥。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.